RNA editing startup launches with $30M based on Stanford and University of Tübingen research
The race to develop new therapies that precisely edit short-lived RNA molecules instead of making irreversible changes to DNA is heating up. A new entrant to the growing field emerged from stealth Tuesday morning with a $30 million initial financing round led by ARCH Venture Partners to make RNA editing therapies for both rare and common diseases.
The startup, called AIRNA, was co-founded in 2021 by Thorsten Stafforst — a University of Tübingen biochemist whose work over the past decade helped spark interest in RNA editing therapies — and Jin Billy Li, a Stanford University biologist who has studied the enzymes that power RNA editing in nature since 2006.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
